MA54289A - Analogues deutérés d'acétyl-leucine - Google Patents

Analogues deutérés d'acétyl-leucine

Info

Publication number
MA54289A
MA54289A MA054289A MA54289A MA54289A MA 54289 A MA54289 A MA 54289A MA 054289 A MA054289 A MA 054289A MA 54289 A MA54289 A MA 54289A MA 54289 A MA54289 A MA 54289A
Authority
MA
Morocco
Prior art keywords
leucine
acetyl
deuterated analogs
deuterated
analogs
Prior art date
Application number
MA054289A
Other languages
English (en)
Inventor
Michiko Mann
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of MA54289A publication Critical patent/MA54289A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA054289A 2018-12-06 2019-12-06 Analogues deutérés d'acétyl-leucine MA54289A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862776297P 2018-12-06 2018-12-06

Publications (1)

Publication Number Publication Date
MA54289A true MA54289A (fr) 2021-10-06

Family

ID=68887086

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054289A MA54289A (fr) 2018-12-06 2019-12-06 Analogues deutérés d'acétyl-leucine

Country Status (13)

Country Link
US (2) US12145899B2 (fr)
EP (1) EP3886986A1 (fr)
JP (3) JP7471298B2 (fr)
KR (2) KR20250022899A (fr)
CN (2) CN120157593A (fr)
AU (1) AU2019391434B2 (fr)
BR (1) BR112021010923A2 (fr)
IL (2) IL283673B2 (fr)
MA (1) MA54289A (fr)
MX (2) MX2021006559A (fr)
SA (1) SA521422185B1 (fr)
SG (1) SG11202106009TA (fr)
WO (1) WO2020115715A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
KR20250022899A (ko) 2018-12-06 2025-02-17 인트라바이오 리미티드 아세틸-류신의 중수소화된 유사체
WO2022264037A1 (fr) * 2021-06-14 2022-12-22 Intrabio Ltd. Dérivés d'acides aminés à chaîne ramifiée pour traiter une maladie
US12403111B2 (en) 2024-02-02 2025-09-02 SynGAP Research Fund Compositions and methods for treating neurodevelopmental disorders

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2293638T3 (es) * 1994-03-25 2008-03-16 Isotechnika, Inc. Mejora de la eficacia de farmacos por deuteracion.
US20060063827A1 (en) 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
US20050026823A1 (en) * 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
MX2013004598A (es) * 2010-10-26 2013-07-17 Teva Pharma Rasagilina enriquesida con deuterio.
KR20150115807A (ko) 2013-02-05 2015-10-14 임파 악치엔게젤샤프트 위치-특이적 비대칭 중수소 풍부 카테콜아민 유도체 및 상기 화합물을 포함하는 약제
HUE069219T2 (hu) * 2016-04-19 2025-02-28 Intrabio Ltd Acetil-leucin vagy gyógyszerészetileg elfogadható sója javított mozgásképességért
HUE052837T2 (hu) * 2016-08-11 2021-05-28 Intrabio Ltd Lizoszóma-tárolási betegségre irányuló gyógyászati készítmények és alkalmazásaik
BR112019002730A2 (pt) * 2016-08-11 2019-05-14 Intrabio Ltd acetil-leucina, ou um sal farmaceuticamente aceitável da mesma, para uso em um método de tratamento de uma doença neurodegenetativa
ES2950452T3 (es) 2017-03-28 2023-10-10 Intrabio Ltd Betahistina, o una sal farmacéuticamente aceptable de la misma, e inhibidor de monoamina oxidasa, para su uso en el tratamiento o la prevención de uno o más síntomas de vértigo en un sujeto
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
MA50399A (fr) 2017-10-18 2020-08-26 Intrabio Ltd Agents thérapeutiques pour mobilité et fonction cognitive améliorées et pour le traitement de maladies neurodégénératives et de troubles de stockage lysosomal
SI3752141T1 (sl) 2018-02-15 2024-09-30 Intrabio Ltd. Acetil-levcin za uporabo pri zdravljenju sindroma nemirnih nog
KR20250022899A (ko) 2018-12-06 2025-02-17 인트라바이오 리미티드 아세틸-류신의 중수소화된 유사체
US10950670B2 (en) * 2018-12-17 2021-03-16 Wuhan China Star Optoelectronics Semiconductor Display Technology Co., Ltd. Display panel
SG11202109512SA (en) 2019-03-02 2021-09-29 Intrabio Ltd Leucine, acetyl leucine, and related analogs for treating disease
EP4650003A3 (fr) 2019-06-28 2026-01-21 IntraBio Ltd Polythérapie avec de l'acétyl-leucine et du miglustat pour le traitement d'une maladie lysosomale
WO2021144720A1 (fr) * 2020-01-13 2021-07-22 Intrabio Ltd Traitement de maladies neurodégénératives tardives chez des porteurs de mutations hétérozygotes du gène npc1
CA3179105A1 (fr) * 2020-05-22 2021-11-25 Michael Strupp Association d'acetylleucine et de 4-aminopyridine ou d'acetazolamide pour traiter l'ataxie

Also Published As

Publication number Publication date
BR112021010923A2 (pt) 2021-08-24
SG11202106009TA (en) 2021-07-29
IL283673B2 (en) 2025-08-01
US12145899B2 (en) 2024-11-19
JP2026016521A (ja) 2026-02-03
EP3886986A1 (fr) 2021-10-06
CN113348018B (zh) 2025-04-01
IL283673A (en) 2021-07-29
AU2019391434B2 (en) 2025-01-09
WO2020115715A1 (fr) 2020-06-11
IL283673B1 (en) 2025-04-01
MX2024005670A (es) 2024-05-30
KR20250022899A (ko) 2025-02-17
IL319687A (en) 2025-05-01
CN113348018A (zh) 2021-09-03
CN120157593A (zh) 2025-06-17
JP7471298B2 (ja) 2024-04-19
US20220024858A1 (en) 2022-01-27
JP2024095769A (ja) 2024-07-10
US20250129011A1 (en) 2025-04-24
KR102765448B1 (ko) 2025-02-07
SA521422185B1 (ar) 2024-04-24
JP2022514823A (ja) 2022-02-16
CA3122223A1 (fr) 2020-06-11
AU2019391434A1 (en) 2021-07-08
KR20210111757A (ko) 2021-09-13
MX2021006559A (es) 2021-08-16

Similar Documents

Publication Publication Date Title
EP3870593A4 (fr) Analogues nucléotidiques
IL283385A (en) Modified gip peptide analogues
MA46180A (fr) Analogues de l'amyline
EP3820473A4 (fr) Synthèse enzymatique d'analogues de nucléosides de type 4'-éthynyle
MA54289A (fr) Analogues deutérés d'acétyl-leucine
DK4122954T3 (da) Novel GLP-1-analoger
EP3429608A4 (fr) Conjugués à libération prolongée d'analogues d'exénatide
MA53085A (fr) Thiophènecarboxamides substitués et analogues comme agents antibactériens
EP3846791A4 (fr) Analogues d'illudine, utilisations associées et leurs procédés de synthèse
EP3325487A4 (fr) Préparation pour analogues d'anticholinergiques à potentiel modéré
EP3893645A4 (fr) Arylméthylurées et hétéroarylméthylurées substituées, analogues de ces dernières et procédés d'utilisation de celles-ci
MA50047A (fr) Administration orale d'analogues peptidiques de glp-1
EP3347334A4 (fr) Déshydrohalogénation d'hydrochlorofluorocarbones
MX383647B (es) Análogos deuterados de etifoxina, sus derivados y usos de estos.
EP3752149A4 (fr) Analogues de quinolone, sels correspondants, compositions et procédé d'utilisation
EP3472176A4 (fr) L'utilité de (+) épicatéchine et de leurs analogues
EP3627775A4 (fr) Synchronisation d'itinéraire
SI3512495T1 (sl) Formulacije prostaciklinskih analogov
EP3920962A4 (fr) Purification d'analogues de glp-1
DK3886813T3 (da) Farmaceutiske formuleringer af cyclosporinanaloger
EP3801363A4 (fr) Ensemble d'ancrage orthodontique
ZA202006370B (en) Deuterated analogs of elacridar
EP3906225C0 (fr) Analogues de pantothénamide
EP3917933A4 (fr) Analogues des duocarmycines
EP3468569A4 (fr) Analogues du glucagon et procédés d'utilisation de ces derniers